含氟达拉滨的预处理方案移植治疗恶性血液病的临床观察
被引量：1
摘要
异基因造血干细胞移植（allo—HSCT）是目前治愈多种恶性肿瘤、先天遗传性疾病和自身免疫性疾病的重要手段，尤其是化疗效果欠佳的高危恶性血液病患者，可以利用移植物抗肿瘤效应（GVT）达到清除恶性克隆的目的。预处理是allo—HSCT成败的关键，应尽可能降低治疗相关死亡率（TRM）和相对危险度（RR），提高无病生存率（DFS）和总生存率（OS）。
出处
《中华血液学杂志》
CAS
CSCD
北大核心
2010年第2期116-118,共3页
Chinese Journal of Hematology
参考文献5
-
1Ferry C, Socie G. Busulfan-cyclophosphamide versus total body irradiation- cyclophosphamide as preparative regimen before allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia: what have we learned? Exp Hematol, 2003, 31:1182- 1186. 被引量：1
-
2Socie G, Clift RA, Blaise D, et al. Busulfan plus cyclophosphamide compared with total-body irradiation plus eyelophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies. Blood, 2001, 98:3569-3574. 被引量：1
-
3Chunduri S, Dobogai LC, Peace D, et al. Fludarabine/i. v. BU conditioning regimen : myeloablative, reduced intensity or both? Bone Marrow Transplant, 2008, 41 : 935-940. 被引量：1
-
4Iravani M, Evazi MR, Mousavi SA, et al. Fludarabine and busulfan as a myeloablative conditioning regimen for allogeneic stem cell transplantation in hlgh-and standard-risk leukemic patients. Bone Marrow Transplant, 2007, 40 : 105-110. 被引量：1
-
5Chae YS, Sohn SK, Kim JG,et al. New myeloablative conditioning regimen with fludarabine and busulfan for allogeneic stem cell transplantation : comparison with BuCy2. Bone Marrow Transplant, 2007, 40:541-547. 被引量：1
同被引文献34
-
1Bostrom B,Enockson K,Johnson A,et al.Plasma pharmacokinetics of high-dose oral busulfan in children and adults undergoing bone marrow transplant.Pediatric Transplant,2003,7 (suppl 3):12-18. 被引量：1
-
2Léger F,Nguyen L,Puozzo C.Exposure equivalence between Ⅳ (0.8 mg/kg) and oral (1 mg/kg) busulfan in adult patients.Eur J Clin Pharmacol,2009,65(9):903-911. 被引量：1
-
3Wall DA,Chan KW,Nieder ML,et al.Safety,efficacy,and pharmacokinetics of intravenous busulfan in children undergoing allogeneic hematopoietic stem cell transplantation.Pediatr Blood Cancer,2010,54(2):291-298. 被引量：1
-
4Vassal G,Michel G,Espérou H,et al.Prospective validation of a novel Ⅳ busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring.Cancer Chemother Pharmacol,2008,61 (1):113-123. 被引量：1
-
5Ansari M,Krajinovic M.Can the pharmacogenetics of GST gene polymorphisms predict the dose of busulfan in pediatric hematopoietic stem cell transplantation? Pharmacogenomics,2009,10(11):1729-1732. 被引量：1
-
6Andersson BS,Madden T,Tran HT,et al.Acute safety and pharmacokinetics of intravenous busulfan when used with oral busulfan and cyclophosphamide as pretransplant conditioning therapy:a phase Ⅰ study.Biol Blood Marrow Transplant,2000,6(5A):548-554. 被引量：1
-
7Andersson BS,Kashyap A,Gian V,et al.Conditioning therapy with intravenous busulfan and cyclophosphamide (Ⅳ BuCy2) for hematologic malignancies prior to allogeneic stem cell transplantation:a phase Ⅱ study.Biol Blood Marrow Transplant,2002,8(3):145-154. 被引量：1
-
8Kashyap A,Wingard J,Cagnoni P,et al.Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation:decreased incidence of hepatic venoocclusive disease (HVOD),HVOD-related mortality,and overall 100-day mortality.Biol Blood Marrow Transplant,2002,8 (9):493-500. 被引量：1
-
9Aggarwal C,Gupta S,Vaughan WP,et al.Improved outcomes in intermediate-and high-risk aggressive non-Hodgkin lymphoma after autologous hematopoietic stem cell transplantation substituting intravenous for oral busulfan in a busulfan,cyclophosphamide,and etoposide preparative regimen.Biol Blood Marrow Transplant,2006,12 (7):770-777. 被引量：1
-
10Cappelli B,Chiesa R,Evangelio C,et al.Absence of VOD in paediatric thalassaemic HSCT recipients using defibrotide prophylaxis and intravenous Busulphan.Br J Haematol,2009,147(4):554-560. 被引量：1
-
1余家密,陈强,叶韵斌.免疫细胞在移植物抗肿瘤效应中的作用[J].中国肿瘤临床与康复,2007,14(2):167-169. 被引量：2
-
2沈悌,张之南.生物治疗——消灭残存肿瘤的新途径[J].中华内科杂志,2000,39(5):293-295. 被引量：1
-
3王维,朴大勋.移植物抗肿瘤效应及其应用于大肠癌治疗的研究进展[J].中国普通外科杂志,2011,20(10):1106-1108. 被引量：1
-
4武利强,张秀侠,周郁鸿.造血干细胞移植在治疗乳腺癌中的应用[J].中华肿瘤防治杂志,2006,13(21):1673-1676. 被引量：2
-
5翟光林,姜藻.移植物抗肿瘤效应及其在实体瘤治疗中的意义[J].东南大学学报（医学版）,2004,23(4):282-285.
-
6费菲,陈宝安.非清髓性异基因造血干细胞移植治疗恶性肿瘤[J].国际肿瘤学杂志,2005,32(1):71-74. 被引量：2
-
7耿建,陈龙邦.非清髓性异基因干细胞移植治疗实体瘤的研究进展[J].医学研究生学报,2005,18(2):178-181.
-
8宣旻,谢晓宝,邱国强.CD_4^+CD_(25)^+调节性T细胞及其在GVHD和GVT中的作用[J].医学综述,2005,11(10):878-881.
-
9唐家宏,徐兵,李琳,李冰.FLT3基因在各种血液肿瘤患者中的表达及其临床意义[J].广东医学,2006,27(7):981-983. 被引量：1
-
10毕林涛,卢振霞.非霍奇金淋巴瘤的单克隆抗体治疗[J].国外医学（肿瘤学分册）,2002,29(4):303-306. 被引量：3
